KR20240158351A - Cd3에 특이적인 탈면역화 항체 - Google Patents

Cd3에 특이적인 탈면역화 항체 Download PDF

Info

Publication number
KR20240158351A
KR20240158351A KR1020247034591A KR20247034591A KR20240158351A KR 20240158351 A KR20240158351 A KR 20240158351A KR 1020247034591 A KR1020247034591 A KR 1020247034591A KR 20247034591 A KR20247034591 A KR 20247034591A KR 20240158351 A KR20240158351 A KR 20240158351A
Authority
KR
South Korea
Prior art keywords
antibody
seq
antigen
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020247034591A
Other languages
English (en)
Korean (ko)
Inventor
마르쿠스 무스마이어
안드레아스 뷜트만
슈테펜 룬츠
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20240158351A publication Critical patent/KR20240158351A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247034591A 2022-03-22 2023-03-21 Cd3에 특이적인 탈면역화 항체 Withdrawn KR20240158351A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22163663 2022-03-22
EP22163663.2 2022-03-22
PCT/EP2023/057248 WO2023180346A1 (en) 2022-03-22 2023-03-21 Deimmunized antibodies specific for cd3

Publications (1)

Publication Number Publication Date
KR20240158351A true KR20240158351A (ko) 2024-11-04

Family

ID=80930505

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034591A Withdrawn KR20240158351A (ko) 2022-03-22 2023-03-21 Cd3에 특이적인 탈면역화 항체

Country Status (9)

Country Link
US (1) US20250206819A1 (cg-RX-API-DMAC7.html)
EP (1) EP4496812A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513714A (cg-RX-API-DMAC7.html)
KR (1) KR20240158351A (cg-RX-API-DMAC7.html)
CN (1) CN118922448A (cg-RX-API-DMAC7.html)
AU (1) AU2023240297A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246381A1 (cg-RX-API-DMAC7.html)
IL (1) IL315591A (cg-RX-API-DMAC7.html)
WO (1) WO2023180346A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
KR20260113057A (ko) * 2023-11-14 2026-07-21 리제너론 파아마슈티컬스, 인크. 조작된 중쇄 가변 도메인 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
ATE356385T1 (de) 2002-06-10 2007-03-15 Algonomics N V Verfahren zur vorhersage der bindungsaffinität der mhc-peptid-komplexe
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
EP2640742B1 (en) 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
WO2015070061A1 (en) * 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
IN2014CN03887A (cg-RX-API-DMAC7.html) 2011-10-27 2015-10-16 Genmab As
CN106459201A (zh) * 2014-05-28 2017-02-22 豪夫迈·罗氏有限公司 结合人和食蟹猴CD3ε的抗体
US11472880B2 (en) * 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
CA3121699A1 (en) 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules

Also Published As

Publication number Publication date
JP2025513714A (ja) 2025-04-30
AU2023240297A1 (en) 2024-10-03
US20250206819A1 (en) 2025-06-26
EP4496812A1 (en) 2025-01-29
CA3246381A1 (en) 2023-09-28
CN118922448A (zh) 2024-11-08
WO2023180346A1 (en) 2023-09-28
IL315591A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
US11472880B2 (en) Humanized antibodies for CD3
JP7847630B2 (ja) Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
JP7058219B2 (ja) Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
EP3160994B1 (en) Multispecific antigen binding proteins
US20200109202A1 (en) Nk cell engaging antibody fusion constructs
TW202227491A (zh) 抗ｒｏｒ１抗體及相關雙特異性結合蛋白
JP2019535650A (ja) ヘテロダイマー免疫グロブリン構造体及びその製造方法
CA3004804A1 (en) Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof
JP7851303B2 (ja) ヒトｃｄ３イプシロンに結合する新規なヒト抗体
AU2019356806B2 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
JP7080219B2 (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
KR20210124993A (ko) 항-pd-1 항체, 이의 항원-결합 단편 및 이의 약학적 용도
JP2019529368A5 (cg-RX-API-DMAC7.html)
US20250206820A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
JP2024516098A (ja) Ｂｃｍａを標的とする多重特異性抗体
US20250206819A1 (en) Deimmunized antibodies specific for cd3
US20220363758A1 (en) Heterodimeric Antibodies That Bind to CD38 and CD3
US20220144956A1 (en) HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
US20250163182A1 (en) Enpp3 and cd3 binding agents and methods of use thereof
CN119487070A (zh) 靶向cd117的抗体
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
TW202241956A (zh) 新穎抗cd24抗體
TW202436345A (zh) 抗ｃｄ３多特異性抗體及使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202